Prokić, Ivana http://orcid.org/0000-0002-0370-1473
Lahousse, Lies
de Vries, Maaike
Liu, Jun
Kalaoja, Marita
Vonk, Judith M.
van der Plaat, Diana A.
van Diemen, Cleo C.
van der Spek, Ashley
Zhernakova, Alexandra
Fu, Jingyuan
Ghanbari, Mohsen
Ala-Korpela, Mika
Kettunen, Johannes
Havulinna, Aki S.
Perola, Markus
Salomaa, Veikko
Lind, Lars
Ärnlöv, Johan
Stricker, Bruno H. C.
Brusselle, Guy G.
Boezen, H. Marike
van Duijn, Cornelia M.
Amin, Najaf
Funding for this research was provided by:
NWO (184.021.007 and 184033111, RFBR 047.017.043, NWO-VIDI 864.13.013, NWO-VIDI 016.178.056)
Longfonds (4.1.13.007)
European Commission (018947)
European Community's Seventh Framework Programme (HEALTH-F4-2007-201413)
Netherlands Heart Foundation (IN-CONTROL CVON grant 2012-03)
European Research Council (715772)
Finnish Academy (139635 and 118065)
Academy of Finland (297338 and 307247)
Novo Nordisk Fonden (NNF17OC0026062)
Article History
Received: 12 April 2020
Accepted: 29 June 2020
First Online: 16 July 2020
Ethics approval and consent to participate
: Both RS and ERF were approved by the Medical Ethics committee of the Erasmus Medical Center and all participants gave informed consent for participation in the study and for evaluation of the available information from their physicians.LLDEEP was approved by the ethics committee of the University Medical Center Groningen and all participants signed an informed consent prior to enrolment.The FINRISK 1997 study was approved by the Ethical Committee of the National Public Health Institute, while the DILGOM study was approved by the Coordinating Ethical Committee of the Hospital District of Helsinki and Uusimaa. All participants have signed an informed consent, allowing the use of their data and samples for studying environmental and genetic risk factors of chronic diseases.The Ethics Committee of the University of Uppsala approved the study and the participants gave informed consent (approval number 00–419).
: Not applicable.
: All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. VS has participated in a conference trip sponsored by Novo Nordisk and received a modest honorarium from the same source for participating in an advisory board meeting. He also has ongoing research collaboration with Bayer Ltd.